VelosBio

VelosBio is an oncology company, developing novel antibody-drug conjugates to treat hematological cancers. The company was acquired by Merck in November 2020.

Overview Structured Data Issues Contributors

velosbio.com

Is a

Organization

Company

Company attributes

Location

Investors

Total Funding Amount (USD)

195,000,000

Latest Funding Round Date

2020

Acquisition Transaction

‌

Acquisition of VelosBio by Merck

Latest Funding Type

Series B

Other attributes

Latest Funding Round Amount (USD)

137,000,000

No article content yet.

Timeline

No Timeline data yet.

Funding Rounds

Products

Acquisitions

SBIR/STTR Awards

Patents

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more companies like VelosBio

Use the Golden Query Tool to find similar companies in the same industry, location, or by any other field in the Knowledge Graph.

Open Query Tool

Access by API

By using this site, you agree to our Terms of Service.